1 month J&J beats quarterly sales and profit estimates on cancer drug sales Yahoo Finance

   X     

1 month These Stocks Moved the Most Today: Netflix, Oracle, Nvidia, Arm, J&J, Procter & Gamble, Travelers, Seagate, and More Yahoo Finance

   X     

1 month Q4 Earnings: 3 Consumer Staples Titans on Deck Zacks

   X     

1 month Kinder Morgan, P&G, J&J, and more set to report earnings Wednesday Investing.com

   X     

1 month Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study Zacks

   X     

1 month Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings? Zacks

   X     

1 month What Analysts Think of Johnson & Johnson Stock Ahead of Earnings Yahoo Finance

   X     

1 month Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week Seeking Alpha

   X     

1 month Pharma Stock Roundup: J&J’s ITCI Buyout, LLY’s Weak Q4 Sales Zacks

   X     

1 month Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know Zacks

   X     

1 month Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves Seeking Alpha

   X     

1 month J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug Zacks

   X     

1 month The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular Zacks

   X     

1 month JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference Zacks

   X     

1 month Johnson & Johnson (JNJ) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) Seeking Alpha

   X     

1 month Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal Yahoo Finance

   X     

1 month What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies Seeking Alpha

   X     

1 month J&J to Acquire Intra-Cellular for About $14.6 Billion Reddit

   X     

1 month J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug Investor's Business Daily

   X     

1 month J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal Investing.com

   X     

1 month Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal Yahoo Finance

   X     

1 month Johnson & Johnson makes $15 billion bet on mental-health drugs MarketWatch

   X     

1 month J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion Investing.com

   X     

1 month Intra-Cellular shares surge amid report J&J exploring possible takeover bid Investing.com

   X     

1 month J&J to buy Intra-Cellular Therapies for $14.6 billion Yahoo Finance

   X     

1 month Johnson & Johnson in talks to acquire Intra-Cellular Therapies Investing.com

   X     

1 month This Stock Is Soaring Amid Johnson & Johnson Takeover Report Yahoo Finance

   X     

1 month J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports Investing.com

   X     

1 month Johnson & Johnson Could Serve As High-Yield Bond Alternative Seeking Alpha

   X     

1 month FDA Accepts J&J’s Filing for Autoimmune Disease Drug Nipocalimab Zacks

   X     

1 month Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO’s Expanded Deal Zacks

   X     

1 month J&J and United Health among Thursday’s market cap stock movers Investing.com

   X     

1 month J&J Pauses Sales of Atrial Fibrillation Device, Stock Down Zacks

   X     

2 months AMD, J&J lead market cap stock movers on Wednesday Investing.com

   X     

2 months J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product Investor's Business Daily

   X     

2 months Johnson & Johnson stock sinks on Varipulse concerns Investing.com

   X     

2 months Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer Seeking Alpha

   X     

2 months Johnson & Johnson stock reaches 52-week low as markets fall FXStreet

   X     

2 months Johnson & Johnson: A Potential Beneficiary Of A Great Rotation Seeking Alpha

   X     

2 months Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors Zacks

   X     

2 months Top Research Reports for NVIDIA, Meta Platforms & Johnson & Johnson Zacks

   X     

2 months Johnson & Johnson: I’m Saying Yes To This Mess Seeking Alpha

   X     

2 months The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer Zacks

   X     

2 months Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report? Zacks

   X     

2 months Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note Zacks

   X     

2 months J&J Trading Near 52-Week Low: Should You Sell the Stock? Zacks

   X     

2 months Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal Yahoo Finance

   X     

2 months J&J Snack Foods: Shares Are Still Too Expensive Seeking Alpha

   X     

2 months Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to Note Zacks

   X     

2 months Johnson & Johnson: Dividend Legend At A Discount Seeking Alpha

   X